Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 10—October 2011

CME ACTIVITY - Research

Clinical Implications of Azole Resistance in Aspergillus fumigatus, the Netherlands, 2007–2009

Jan W.M. van der LindenComments to Author , Eveline Snelders, Greetje A. Kampinga, Bart J.A. Rijnders, Eva Mattsson, Yvette J. Debets-Ossenkopp, Ed J. Kuijper, Frank H. Van Tiel, Willem J.G. Melchers, Paul E. Verweij, and Kuijper

Author affiliations: Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands (J.W.M. van der Linden, E. Snelders, W.J.G. Melchers, P.E. Verweij); Groningen University Medical Centre, Groningen, the Netherlands (G.A. Kampinga); Erasmus Medical Centre, Rotterdam, the Netherlands (B.J.A. Rijnders); Utrecht University Medical Centre, Utrecht, the Netherlands (E. Mattsson); Vrije University Medical Centre, Amsterdam, the Netherlands (Y.J. Debets-Ossenkopp); Leiden University Medical Centre, Leiden, the Netherlands (E.J. Kuijper); Maastricht University Medical Centre, Maastricht, the Netherlands (F.H. van Tiel)

Main Article

Table 1

Characteristics of screened susceptible and resistant isolates of Aspergillus spp., the Netherlands, 2007–2009*

Source and species No. (%) susceptible, n = 1,978 No. (%) resistant, n = 84
Specimen source
Sputum 1,397 (70.6) 64 (76.2)
Ear swab 176 (8.9) 3 (3.6)
BAL fluid 97 (4.9) 6 (7.1)
Bronchus secretion 66 (3.3) 2 (2.4)
Throat/nasal swab 66 (3.3) 1 (1.2)
Tissue 55 (2.8) 5 (6.0)
Skin swab/nail 38 (1.9) 1 (1.2)
Mouth wash 26 (1.3) 1 (1.2)
Pus/wound swab 16 (0.8) 1 (1.2)
Bronchial wash 11 (0.6) 0
Feces 8 (0.4) 0
Unknown 22 (1.1) 0



Species
A. fumigatus 1,710 (86.5) 82 (97.6)
A. flavus 98 (5.0) 0
A. niger 52 (2.6) 2 (2.4)
A. terreus 35 (1.8) 0
A. nidulans 14 (0.7) 0
A. versicolor 13 (0.7) 0
A. glaucus 6 (0.3) 0
Unknown 50 (2.5) 0

*BAL, bronchoalveolar lavage.

*BAL, bronchoalveolar lavage.

*BAL, bronchoalveolar lavage.

Main Article

TOP